Roche Gets CE Mark for New Molecular Blood Screening Systems | GenomeWeb

NEW YORK (GenomeWeb) — Roche said today that it has received CE marking for the cobas 6800/8800 automated molecular testing systems for blood and plasma donor screening.

The systems are now commercially available in all markets accepting the CE mark in Europe, Latin America, Middle East, Africa, and Asia.

Each system provides results for the first 96 tests in less than 3.5 hours, with the cobas 6800 delivering up to 384 results in an eight-hour shift, and the cobas 8800 generating up to 960 results in the same amount of time, Roche said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.

Mar
02
Sponsored by
VelaDx

This online seminar will highlight recent advances in the use of next-generation sequencing to detect drug-resistant mutations in patients with HIV or HCV. 

Mar
09
Sponsored by
Bio-Rad

This webinar will discuss how next-generation sequencing and digital PCR can be used in a complementary manner for liquid biopsies in order to improve patient care.